The field of cancer immunotherapies was buoyed last year by the FDA’s approval of the first autologous CAR-T drugs on the market, Novartis’ Kymriah and Gilead’s Yescarta. But, many drug makers are already looking in a new direction — off-the-shelf, or allogeneic, CAR-T therapies. In autologous therapies, like Kymriah and Yescarta, scientists isolate T cells from…
For years, umbilical cord blood (UCB) transplant was considered an acceptable alternative unrelated donor graft for the treatment of leukemia including reconstituting a patient’s immune system. Typically UCB transplants could be performed without the worry of precise patient-donor HLA-compatibility. To date, more than 35,000 cord blood transplants have been conducted worldwide. As use of the…
One of the core components of our MatchSourceSM technology platform is a powerful, predictive search algorithm we call HapLogicSM. We sat down with Katie Howe, Ph.D., manager, Immunogenetic Operations and Research, and Caleb Kennedy, Ph.D., senior manager, Bioinformatics Research, to learn more about HapLogic and the important role search algorithms play in allogeneic drug development.